Single Nucleotide Polymorphism (SNP) Panels and Risk Assessment in Women Undergoing Mammography

Completed

Conditions studied: Mammography

In brief

The primary objective is to compare the predicted lifetime risk values produced by SNP panel assessment to the risk values produced by the prediction models that are most commonly used. A second objective is to examine whether the incorporation of risk assessment panels (standard or SNP based) can improve the positive value of breast biopsies in women with BIRADS 4 mammograms.

Key facts

Study ID

NCT01124019

Run by

Abramson Cancer Center at Penn Medicine

People needed

1600

Starts

2010-02-01

Expected to finish

2012-10-01

Last updated by the study team

2019-03-07

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women between the ages of 40 and 65 years old undergoing screening mammography at the University of Pennsylvania Health System and women undergoing biopsy as the result of a BIRADS category 4 mammogram result.

You may not qualify if…

• Women will be excluded if they have a personal history of breast or ovarian cancer, DCIS, or mantle radiation, or known BRCA 1/2 mutation in self or in family members.
• In addition, women younger than 40 or older than 65 will be excluded if they are in the screening mammography population of potential participants.

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.